PMID- 17825623
OWN - NLM
STAT- MEDLINE
DCOM- 20071220
LR  - 20070928
IS  - 1471-4906 (Print)
IS  - 1471-4906 (Linking)
VI  - 28
IP  - 10
DP  - 2007 Oct
TI  - HLA and KIR polymorphisms affect NK-cell anti-tumor activity.
PG  - 437-41
AB  - Killer cell immunoglobulin-like receptors (KIRs) and their cognate human 
      leukocyte antigen (HLA) ligands are key to the maintenance of natural killer (NK) 
      cell tolerance. The gene complexes encoding both KIRs and HLA ligands are 
      extremely polymorphic. Because the extent of NK cell inhibition varies with the 
      allelic forms expressed, NK cell tolerance can be broken more easily in some 
      individuals than in others. This explains why particular combinations of KIR and 
      HLA genes are associated with an increased risk of autoimmune diseases or with 
      more efficient antiviral responses. Breaking of NK cell tolerance might be 
      prerequisite to kill leukemic blasts. At present, there are ample indications 
      that NK cells can eradicate acute myeloid leukemia blasts in patients with a 
      favorable combination of HLA and KIR genes. Selecting these individuals for 
      clinical trials should give insight into the feasibility of anti-tumor therapy 
      mediated through NK cells.
FAU - Passweg, Jakob R
AU  - Passweg JR
AD  - Division of Hematology, University Hospital Geneva, CH-1211 Geneva 14, 
      Switzerland.
FAU - Huard, Bertrand
AU  - Huard B
FAU - Tiercy, Jean-Marie
AU  - Tiercy JM
FAU - Roosnek, Eddy
AU  - Roosnek E
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20070907
PL  - England
TA  - Trends Immunol
JT  - Trends in immunology
JID - 100966032
RN  - 0 (HLA Antigens)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Autoimmunity
MH  - Cytotoxicity, Immunologic
MH  - HLA Antigens/*genetics/immunology/metabolism
MH  - Humans
MH  - Immune Tolerance
MH  - Immunotherapy
MH  - Killer Cells, Natural/*immunology/metabolism
MH  - Leukemia, Myeloid, Acute/immunology/therapy
MH  - Neoplasms/*immunology
MH  - *Polymorphism, Genetic
MH  - Receptors, KIR/*genetics/immunology/metabolism
EDAT- 2007/09/11 09:00
MHDA- 2007/12/21 09:00
CRDT- 2007/09/11 09:00
PHST- 2007/07/20 00:00 [received]
PHST- 2007/07/20 00:00 [revised]
PHST- 2007/07/20 00:00 [accepted]
PHST- 2007/09/11 09:00 [pubmed]
PHST- 2007/12/21 09:00 [medline]
PHST- 2007/09/11 09:00 [entrez]
AID - S1471-4906(07)00188-3 [pii]
AID - 10.1016/j.it.2007.07.008 [doi]
PST - ppublish
SO  - Trends Immunol. 2007 Oct;28(10):437-41. doi: 10.1016/j.it.2007.07.008. Epub 2007 
      Sep 7.